CN114206859A - 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途 - Google Patents

3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途 Download PDF

Info

Publication number
CN114206859A
CN114206859A CN202080035787.9A CN202080035787A CN114206859A CN 114206859 A CN114206859 A CN 114206859A CN 202080035787 A CN202080035787 A CN 202080035787A CN 114206859 A CN114206859 A CN 114206859A
Authority
CN
China
Prior art keywords
compound
pain
formula
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080035787.9A
Other languages
English (en)
Inventor
王友鑫
张玲玲
丁强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Leado Pharmatech Co ltd
Original Assignee
Shanghai Leado Pharmatech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2019/100846 external-priority patent/WO2020035040A1/zh
Priority claimed from CN202010093736.3A external-priority patent/CN111943943A/zh
Application filed by Shanghai Leado Pharmatech Co ltd filed Critical Shanghai Leado Pharmatech Co ltd
Publication of CN114206859A publication Critical patent/CN114206859A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

本发明涉及3‑芳氧基‑3‑五元杂芳基‑丙胺类化合物及其晶型和用途。具体地，本发明提供一种化合物，或其药学上可接受的盐、或其前药，所述化合物具有式I结构。本发明所述的化合物，或其药学上可接受的盐、或其前药对瞬时受体电位通道蛋白(TPR)具有优异的抑制作用，并对瞬时受体电位通道蛋白相关的疾病具有良好的治疗作用。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202080035787.9A 2019-05-16 2020-05-14 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途 Pending CN114206859A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201910411311 2019-05-16
CN201910411311X 2019-05-16
PCT/CN2019/100846 WO2020035040A1 (zh) 2018-08-17 2019-08-15 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途
CNPCT/CN2019/100846 2019-08-15
CN2020100937363 2020-02-14
CN202010093736.3A CN111943943A (zh) 2019-05-16 2020-02-14 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
PCT/CN2020/090354 WO2020228789A1 (zh) 2019-05-16 2020-05-14 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途

Publications (1)

Publication Number Publication Date
CN114206859A true CN114206859A (zh) 2022-03-18

Family

ID=73289829

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080035787.9A Pending CN114206859A (zh) 2019-05-16 2020-05-14 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途

Country Status (6)

Country Link
US (1) US20220213075A1 (zh)
EP (1) EP3971181A4 (zh)
JP (1) JP7429998B2 (zh)
CN (1) CN114206859A (zh)
AU (1) AU2020276005B2 (zh)
WO (1) WO2020228789A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115135644A (zh) * 2020-02-14 2022-09-30 漳州片仔癀药业股份有限公司 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型
CN115703767A (zh) * 2021-08-12 2023-02-17 上海璃道医药科技有限公司 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094262A1 (en) * 2001-05-18 2002-11-28 Eli Lilly And Company Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
CN107840845A (zh) * 2016-09-19 2018-03-27 上海璃道医药科技有限公司 胺类化合物的新用途
WO2018115069A1 (en) * 2016-12-20 2018-06-28 Laboratorios Del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US20070116643A1 (en) * 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
WO2008077645A1 (en) * 2006-12-22 2008-07-03 Synthon B.V. Process for making duloxetine and related compounds
CN101613347B (zh) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物及其医药用途
TW201026700A (en) 2008-12-22 2010-07-16 Hydra Biosciences Inc Compositions useful for treating disorders related to TRPA1
EP2332930A1 (en) * 2009-11-23 2011-06-15 Laboratorios Del. Dr. Esteve, S.A. Salts of duloxetine and NSAIDs for the treatment of pain
CN109758452A (zh) * 2014-09-25 2019-05-17 石药集团中奇制药技术（石家庄）有限公司 胺类化合物治疗疼痛的医药用途
CN107625762B (zh) * 2016-07-25 2021-11-19 上海璃道医药科技有限公司 萘环类药物的新用途
EP3339304A1 (en) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Quinoline and isoquinoline derivatives for treating pain and pain related conditions
CN108947989B (zh) * 2017-05-19 2021-07-02 北京君科华元医药科技有限公司 氘代光学异构体及其医药用途
CN112566909B (zh) * 2018-08-17 2023-01-03 上海璃道医药科技有限公司 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途
JP7283669B2 (ja) * 2018-08-17 2023-05-30 チャンチョウ ピエン ツェ フアン ファーマシューティカル カンパニー リミテッド ３－アリールオキシ－３－アリール－プロピルアミン化合物およびその用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094262A1 (en) * 2001-05-18 2002-11-28 Eli Lilly And Company Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
CN107840845A (zh) * 2016-09-19 2018-03-27 上海璃道医药科技有限公司 胺类化合物的新用途
WO2018115069A1 (en) * 2016-12-20 2018-06-28 Laboratorios Del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. R. BOOT ET AL: "Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, pages 5395, XP004580536, DOI: 10.1016/j.bmcl.2004.08.005 *
JOHN R. CASHMAN ET AL: "Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 17, no. 14, pages 6890 *
REGISTRY: "RN 1181660-13-8", STN COLUMBUS, pages 1 *
张艳平等: "度洛西汀衍生物的设计、合成及抗抑郁活性", 药学学报, vol. 45, no. 7, pages 869 *

Also Published As

Publication number Publication date
US20220213075A1 (en) 2022-07-07
EP3971181A1 (en) 2022-03-23
AU2020276005B2 (en) 2023-05-18
EP3971181A4 (en) 2023-11-08
AU2020276005A1 (en) 2022-01-20
JP2022532746A (ja) 2022-07-19
JP7429998B2 (ja) 2024-02-09
WO2020228789A1 (zh) 2020-11-19

Similar Documents

Publication Publication Date Title
CN112566909B (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途
CN112654616B (zh) 3-芳氧基-3-芳香基-丙胺类化合物及其用途
AU2014236719B2 (en) Compounds and methods for inducing chondrogenesis
CN108558831B (zh) 取代吡咯-4-烷基胺类化合物及其用途
JP5819954B2 (ja) 抗炎症剤、免疫調節剤及び抗増殖剤としての化合物の新規カルシウム塩
CN1964965A (zh) 硫取代的三环和双环芳族甲烷亚磺酰基衍生物
KR20210102887A (ko) 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
CN114206859A (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
CN111943943A (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
KR20120099212A (ko) 트라마돌 및 콕시브의 공결정
WO2021160134A1 (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型
AU2017239419B2 (en) Benzenesulfonyl-asymmetric ureas and medical uses thereof
RU2603770C2 (ru) Замещенные пиразинопиримидиноны как блокаторы trpa1 каналов, фармацевтическая композиция, способы их получения и применения
JP6078153B2 (ja) チアンジンアミド誘導体、並びにその医薬組成物及び使用
JP2021505573A (ja) ベータ−２選択的アドレナリン性受容体アゴニスト
CA2860489C (en) Deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor
WO2022119928A1 (en) Imidazole compounds as inhibitors of enpp1
WO2002094820A1 (en) Crystalline salts of 2-(4-{2-[2-hydroxy-3-(2-thiophen-2-yl-phenoxy)-propylamino]-2-methyl-propyl}-phenoxy)-nicotinonitrile

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination